Option Care Health stock
OPCHNASDAQOption Care Health, Inc., HealthcareISIN US68404L2016
64Score 64 out of 100, Neutral
Price and trend
81 / 100
Price history
+11% in one yearThe chart shows daily closes over 20 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 21% above it.
Since October 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 64).
The price is 13% below its 52-week high. Largest decline in 20 years: 94% (July 2013 to December 2016).
Chart figures for advanced users
- SMA 50$27.78
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$26.15
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)64
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDbelow the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$19.52
- The lowest closing price of the last twelve months.
- Resistance$36.59
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Option Care Health, Inc. belongs to the Medical (Care Facilities) industry (United States) and, with a market value of $4.75B, is number 18 of 56 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $5.65B (up 13% year on year) and earnings of $207.59M (down 2%).
- For fiscal 2026, analysts expect on average revenue of $5.76B (up 2%) and adjusted earnings per share of $1.88 (up 9.6%).
Show more
- MEQIRI Score 64 out of 100 (Neutral): rank 230 of 714 in Healthcare, median 53.
- The P/E is 22.2 (Medical (Care Facilities) median 19.4, own median of recent years 24.9).
- Our model puts fair value at $41.38, with the price 23% below it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Share buybacksShare count down 10% since 2020.Capital allocation 64
- Earnings turn into cashFree cash flow 129% of earnings over the last 12 months.Fundamentals 59
Weaknesses
- Volatile share priceVolatility 52% a year over the last 12 months.Stability 58
Its standout strengths are technical analysis and momentum, while profitability holds the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 65 to 64.
The fundamentals are in the middle range.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk medium
How well MEQIRI warnsIn the middle among smaller stocks.
From 2016 to 2025, 20 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What drives the risk
- high price swings
Valuation
Valuation signal
Modestly undervaluedIn our model the price counts as cheap below $29.56 and expensive above $68.97 (uncertainty high, based on the price swings of the past year).
The two parts of the fair value come to $55.08 (cash-flow model) and $27.68 (industry comparison), and the gap between them shows how uncertain the estimate is.
Calculated with a cost of equity of 8.8%. At 9.8% the fair value would be $36.80, at 7.8% it would be $48.25.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (19.4).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 4% on the twelve months before. Revenue has grown strongly since 2010, at around 19% per year. From 2010 revenue only includes continuing operations, sold or discontinued divisions have been reclassified. Earlier years are not comparable and not shown, and the margins for 2010 are not measured.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 18%, operating 6%, net 4%. From 2010 revenue only includes continuing operations, sold or discontinued divisions have been reclassified. Earlier years are not comparable and not shown, and the margins for 2010 are not measured.
Debt & balance sheet
latest quarterModerate debt, and interest is adequately covered.
Earnings
- Next earnings
- 23 Feb 2027in 103 days
- Last reported
- 4 Nov 2026EPS reported $0.49 (expected $0.49)in line with expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- $1.88+0.2%
- Revenue
- $5.76B+0.1%
- Earnings per share
- $2.09+0.2%
- Revenue
- $6.13B+0.1%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook confirmed
Share price after the results: −0.1%New 2026 range given: adjusted EBITDA $480 million to $495 million, adjusted EPS $1.85 to $1.92, with no visible comparison to before.
“We now expect adjusted EBITDA to be in the range of $480 million to $495 million and we expect adjusted EPS to be in the range of $1.85 to $1.92.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 29 Jul 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases or sales in the last 6 months.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Option Care Health
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 64
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Care Facilities)
The next larger and next smaller companies by market value
- ChemedCHE $7.17B75
- Fortis HealthcareFORTIS.NS $6.22B53
- Concentra Group Holdings ParentCON $5.5B69
- LifeStance Health GroupLFST $5.46B57
- Hims & Hers HealthHIMS $4.68B35
- MedicoverMCOV-B.ST $4.02B62
- Acadia HealthcareACHC $3.61B47
- Surgery PartnersSGRY $3.49B53
ETFs that hold Option Care Health
Held by 14 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| iShares Ageing Population UCITS ETF2B77 | 0.41% | 0.40% | €807M |
| L&G Russell 2000 US Small Cap Quality UCITS ETFETLZ | 0.27% | 0.30% | €185.82M |
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.17% | 0.30% | €2.17B |
Show 5 more
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.17% | 0.30% | €4.22B |
| State Street SPDR S&P 400 U.S. Mid Cap UCITS ETF (Acc)SPY4 | 0.14% | 0.30% | €5.27B |
| iShares MSCI World Small Cap CTB Enhanced ESG UCITS ETFCBUG | 0.14% | 0.35% | €434.1M |
| iShares MSCI USA Small Cap CTB Enhanced ESG UCITS ETFSXRG | 0.12% | 0.43% | €2.48B |
| State Street SPDR MSCI USA Small Cap Value Weighted UCITS ETFZPRV | 0.11% | 0.30% | €944.34M |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 11 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 22 Nov 2024)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.